<SEC-DOCUMENT>0001062993-18-001328.txt : 20180323
<SEC-HEADER>0001062993-18-001328.hdr.sgml : 20180323
<ACCEPTANCE-DATETIME>20180323154302
ACCESSION NUMBER:		0001062993-18-001328
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180320
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180323
DATE AS OF CHANGE:		20180323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		18710017

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>March 20,
2018</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="50%" align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="50%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)<BR>[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))<BR>[&nbsp;&nbsp;
]&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))<BR></P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=right>Emerging growth company [&nbsp;&nbsp; ]</P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [&nbsp;&nbsp; ]</P>
<P align=justify><B>Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing that Lexaria has filed a
new patent application with the United States Patent and Trademark Office is
filed as exhibit 99.1 to this current report and is hereby incorporated by
reference. </P>
<P align=justify>A copy of the news release announcing that Lexaria has received
a new Notice of Allowance from the United States Patent and Trademark Office is
filed as exhibit 99.2 to this current report and is hereby incorporated by
reference. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 9.01</B> </TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits</B> </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated March 20,
      2018 </a></TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-2.htm">99.2 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-2.htm">Press Release dated March 22,
      2018 </a></TD></TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>LEXARIA BIOSCIENCE CORP.</B> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; March 22, 2018 </TD>
    <TD align=left width="50%">&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Files New Patent Application for Enhanced Transdermal
Delivery System </B></P>
<P align=justify>Kelowna, British Columbia &#150; March 20, 2018 &#150; Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;), a drug delivery
platform innovator, is pleased to announce it has filed a new patent application
with the United States Patent and Trademark Office (&#147;USPTO&#148;) for use of
DehydraTECH<SUP>TM</SUP> to improve the speed and quantity of absorption of
active pharmaceutical ingredients (&#147;API&#148;) through the skin. </P>
<P align=justify>The patent application follows the recently announced
successful laboratory evaluation of DehydraTECH<SUP>TM</SUP> in the transdermal
delivery of cannabidiol (&#147;CBD&#148;) that showed as much as a 225% increase in CBD
permeability compared to control formulations tested with leading commercial
penetration enhancers; and almost a 1,900% increase in CBD permeability compared
to a control formulation that was devoid of both the DehydraTECH<SUP>TM</SUP>
technology or any commercial penetration enhancers. The original research
protocols were overseen by Lexaria President John Docherty and represent a
unique, new and improved method of transdermal delivery for cannabinoids and
potentially many other active ingredients. </P>
<P align=justify>In the patent application, Lexaria has applied for patent
protection for the delivery of all of the active ingredient classes already
identified in its other issued and pending patent applications including
cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and
phosphodiesterase inhibitors, as well as a broad range of additional active
ingredients commonly found in topical products today that may benefit from
enhanced skin permeability performance in concert with the
DehydraTECH<SUP>TM</SUP> technology. </P>
<P align=justify>The Company believes that its DehydraTECH<SUP>TM</SUP>
technology could drive significant innovation and improvement for the delivery
of active ingredients through topical products, transdermal patches, cosmetics
and many other skin-oriented consumer product formats. Lexaria will initiate
third-party licensing discussions for this new transdermal application of
DehyrdaTECH<SUP>TM</SUP> as soon as possible. </P>
<P align=justify>Lexaria&#146;s patented DehydraTECH&#153; technology is focused on
improved delivery<I> </I>methodologies of many commonly used API substances. As
such, it provides an additional layer of effectiveness that is designed to
harmonize with the intellectual property of third parties. Both patented and
generic API substances can utilize Lexaria&#146;s patented technology. Lexaria&#146;s long
term strategy is to partner with the world&#146;s leading firms as they deliver
best-of-class products to their existing large consumer groups.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify><b>About Lexaria <br>
</b>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over
40 countries around the world and has patents granted in the USA and in
Australia for utilization of its DehydraTECH<SUP>TM </SUP>delivery technology.
Lexaria&#146;s technology provides increases in intestinal absorption rates; more
rapid delivery to the bloodstream; and important taste-masking benefits, for
orally administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
<U><FONT color=#0000ff>www.lexariabioscience.com </FONT></U></P>
<IMG
src="tw.jpg"
border=0> For regular updates, connect with Lexaria on Twitter (<u>https://twitter.com/lexariacor</u>p)<BR>
<IMG
src="fb.jpg"
border=0>&nbsp;and on Facebook <U>http://tinyurl.com/y8vzcaam </U>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U>www.NetworkNewsWire.com
</U><BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional patent protection will be realized or
that patent achievements will deliver material results. Such forward-looking
statements are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and uncertainties, and there
can be no assurance that other factors will not affect the accuracy of such
forward-looking statements. Factors which could cause actual results to differ
materially from those estimated by the Company include, but are not limited to,
government regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition, scientific discovery, the patent application
and approval process and other factors which may be identified from time to time
in the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance the Company will be capable
of developing, marketing, licensing, or selling edible products containing
cannabinoids or any other active ingredient. There is no assurance that any
planned corporate activity, scientific research or study, business venture,
technology licensing pursuit, patent application or allowance, consumer study,
or any initiative will be pursued, or if pursued, will be successful. There is
no assurance that any of Lexaria&#146;s postulated uses, benefits, or advantages for
the patented and patent-pending technology will in fact be realized in any
manner or in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria-associated products are not intended to
diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.2 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.2 </B></P>
<P align=center><B>Lexaria Bioscience Corp. Receives New U.S. Patent Allowance
for &#147;Composition of </B><BR><B>Matter&#148; Cannabinoid Delivery </B><BR></P>
<P align=justify>Kelowna, British Columbia &#150; March 22, 2018 &#150; Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;), a drug delivery
platform innovator, announces it has received a new Notice of Allowance from the
United States Patent and Trademark Office (&#147;USPTO&#148;) providing for &#147;composition
of matter&#148; claims that protect the specific combination of substances which
enable improved taste and bioabsorption properties of its DehydraTECH&#153;
technology for the delivery of cannabinoids. This is a significant addition to
Lexaria&#146;s existing manufacturing &#147;method of use&#148; patent rights previously
granted.</P>
<P align=justify>&#147;This Notice of Allowance applies to the delivery of both
psychoactive and non-psychoactive cannabinoids as lipophilic active agents
formulated together with the edible fatty acids that enable the powerful
bioavailability and taste enhancing properties of the DehydraTECH&#153; technology,&#148;
said John Docherty, President. &#147;This allowance has been granted by the USPTO
upon review of the compelling scientific data Lexaria has amassed demonstrating
its significant bioavailability performance enhancement properties.&#148;</P>
<P align=justify>Under USPTO practice, there is no opposition period between
allowance and issuance. The patent application number is 15/225,802, &#147;Food and
Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use
Thereof&#148;. As has been Lexaria&#146;s experience in the past, the Company expects the
formal granting of the new patent within roughly one hundred days or less. </P>
<P align=justify>Lexaria has additional patent applications that remain within
the USPTO process, of both the composition of matter and process varieties.
Lexaria will continue to develop and strengthen its patent portfolio in the USA,
Canada, and internationally and expects further patent awards this year. As its
patent portfolio increases, Lexaria will be better able to commercialize its
technologies and defend its intellectual property. </P>
<P align=justify>Lexaria&#146;s patented DehydraTECH&#153; technology is focused on
improved delivery<I> </I>methodologies of many commonly used active
pharmaceutical ingredient (&#147;API&#148;) substances. As such, it provides an additional
layer of effectiveness that is designed to harmonize with the intellectual
property of third parties. Both patented and generic API substances can utilize
Lexaria&#146;s patented technology. Lexaria&#146;s long term strategy is to partner with
the world&#146;s leading firms as they deliver best-of-class products to their
existing large consumer groups.</P>
<hr style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noshade size=5>
<a name=page_2></a>
<P align=justify><B>About Lexaria <BR>
</B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over
40 countries around the world and has patents granted in the USA and in
Australia for utilization of its DehydraTECH<SUP>TM </SUP>delivery technology.
Lexaria&#146;s technology provides increases in intestinal absorption rates; more
rapid delivery to the bloodstream; and important taste-masking benefits, for
orally administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
<U>www.lexariabioscience.com </U></P>
<IMG
src="tw.jpg"
border=0> For regular updates, connect with Lexaria on Twitter (<u>https://twitter.com/lexariacorp</u>)<BR>
<img
src="fb.jpg"
border=0>&nbsp;and on Facebook <U>http://tinyurl.com/y8vzcaam </U>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U>www.NetworkNewsWire.com
</U><BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing cannabinoids or any
other active ingredient. There is no assurance that any planned corporate
activity, scientific research or study, business venture, technology licensing
pursuit, patent application or allowance, consumer study, or any initiative will
be pursued, or if pursued, will be successful. There is no assurance that any of
Lexaria&#146;s postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). Lexaria-associated products are not intended to diagnose, treat, cure or
prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tw.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  Z #$# 2(  A$! Q$!_\0
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A45HZTVK7,%A:*=^48B! %4  >@IU+161T6L%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>fb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fb.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  V #,# 2(  A$! Q$!_\0
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M6!0L3'Y1C%0VY83ILSNSQBM913@0OB/3Z*!THK@L=($9&#7F^J6;66H2P$<
MY4^W:O2*SM8TB'4XOF^650=KBM*4^5D3CS(\]&0>M=AXB!'AR$\\%?Y5S5WI
M=Y9.5E@? Z,!D$4V2ZNYX5BDDD=%Z*><5U37-9IF2=MRKTQ6OX9LC=ZFKD9C
MB^8GUJ+3]#O;YUQ$4CSDNW%=QI]A#I]NL,*\#J>Y-35JI*R'"-]2SR**6BN*
CQN%%%%, (!&",CWJ,6\(;<(8P?4**** )**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
